Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC
Status:
Recruiting
Trial end date:
2021-10-30
Target enrollment:
Participant gender:
Summary
The combination treatment of protein kinase B (AKT) inhibitor, afuresertib, with androgen
synthesis enzyme inhibitor, LAE001, may provide an effective treatment for metastatic
castration resistant prostate cancer (m-CRPC) patients who have progressed/drug resistant
following prior standard care treatments of any anti-androgen. This study intends to identify
the most appropriate combined doses of LAE001/prednisone and afuresertib in m-CRPC patients
who have progressive disease or are intolerant of 2 prior standard treatments of any
anti-androgen or anti-androgen treatment plus chemotherapy.